Literature DB >> 18006625

Rescue of pituitary function in a mouse model of isolated growth hormone deficiency type II by RNA interference.

Nikki Shariat1, Robin C C Ryther, John A Phillips, Iain C A F Robinson, James G Patton.   

Abstract

Splicing mutations in the human GH (hGH) gene (GH-1) that cause skipping of exon 3 result in a form of GH deficiency termed isolated GH deficiency type II (IGHD II). The GH-1 gene contains five exons; constitutive splicing produces the wild-type 22-kDa hormone, whereas skipping of exon 3 results in transcripts encoding a 17.5-kDa isoform that acts as a dominant-negative to block secretion of the wild-type hormone. Common characteristics of IGHD II include short stature due to impaired bone elongation, growth, and, in severe cases, anterior pituitary hypoplasia. Typically, IGHD II is treated by sc delivery of hGH, which can rescue stature but, unfortunately, does not inhibit pituitary hypoplasia. Direct destruction of transcripts encoding the dominant-negative 17.5-kDa isoform should both rescue stature and prevent hypoplasia. Here, we have used delivery of short hairpin RNAs to rescue a murine model of IGHD II by specifically targeting transcripts encoding the 17.5-kDa isoform using RNA interference. To our knowledge, this is the first example where a short hairpin RNA has been expressed to specifically degrade an incorrectly spliced transcript and rescue a dominant-negative disease phenotype in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006625      PMCID: PMC2219309          DOI: 10.1210/en.2007-1360

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  29 in total

Review 1.  The silent treatment: siRNAs as small molecule drugs.

Authors:  D M Dykxhoorn; D Palliser; J Lieberman
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

2.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity.

Authors:  Aimee L Jackson; Julja Burchard; Janell Schelter; B Nelson Chau; Michele Cleary; Lee Lim; Peter S Linsley
Journal:  RNA       Date:  2006-05-08       Impact factor: 4.942

3.  Variability of isolated autosomal dominant GH deficiency (IGHD II): impact of the P89L GH mutation on clinical follow-up and GH secretion.

Authors:  Souzan Salemi; Shida Yousefi; Kurt Baltensperger; Iain C A F Robinson; Andrée Eblé; Dominique Simon; Paul Czernichow; Gerhard Binder; Emmanuel Sonnet; Primus E Mullis
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

4.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.

Authors:  Dirk Grimm; Konrad L Streetz; Catherine L Jopling; Theresa A Storm; Kusum Pandey; Corrine R Davis; Patricia Marion; Felix Salazar; Mark A Kay
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

5.  An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection.

Authors:  Deborah Palliser; Dipanjan Chowdhury; Qing-Yin Wang; Sandra J Lee; Roderick T Bronson; David M Knipe; Judy Lieberman
Journal:  Nature       Date:  2005-11-23       Impact factor: 49.962

6.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

Authors:  David V Morrissey; Jennifer A Lockridge; Lucinda Shaw; Karin Blanchard; Kristi Jensen; Wendy Breen; Kimberly Hartsough; Lynn Machemer; Susan Radka; Vasant Jadhav; Narendra Vaish; Shawn Zinnen; Chandra Vargeese; Keith Bowman; Chris S Shaffer; Lloyd B Jeffs; Adam Judge; Ian MacLachlan; Barry Polisky
Journal:  Nat Biotechnol       Date:  2005-07-24       Impact factor: 54.908

7.  RNAi-mediated gene silencing in non-human primates.

Authors:  Tracy S Zimmermann; Amy C H Lee; Akin Akinc; Birgit Bramlage; David Bumcrot; Matthew N Fedoruk; Jens Harborth; James A Heyes; Lloyd B Jeffs; Matthias John; Adam D Judge; Kieu Lam; Kevin McClintock; Lubomir V Nechev; Lorne R Palmer; Timothy Racie; Ingo Röhl; Stephan Seiffert; Sumi Shanmugam; Vandana Sood; Jürgen Soutschek; Ivanka Toudjarska; Amanda J Wheat; Ed Yaworski; William Zedalis; Victor Koteliansky; Muthiah Manoharan; Hans-Peter Vornlocher; Ian MacLachlan
Journal:  Nature       Date:  2006-03-26       Impact factor: 49.962

8.  Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.

Authors:  G Scott Ralph; Pippa A Radcliffe; Denise M Day; Janine M Carthy; Marie A Leroux; Debbie C P Lee; Liang-Fong Wong; Lynsey G Bilsland; Linda Greensmith; Susan M Kingsman; Kyriacos A Mitrophanous; Nicholas D Mazarakis; Mimoun Azzouz
Journal:  Nat Med       Date:  2005-03-13       Impact factor: 53.440

9.  Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

Authors:  Cédric Raoul; Toufik Abbas-Terki; Jean-Charles Bensadoun; Sandrine Guillot; Georg Haase; Jolanta Szulc; Christopher E Henderson; Patrick Aebischer
Journal:  Nat Med       Date:  2005-03-13       Impact factor: 53.440

Review 10.  Therapeutic short hairpin RNA expression in the liver: viral targets and vectors.

Authors:  D Grimm; M A Kay
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

View more
  7 in total

1.  Pharmacologic correction of dominant-negative GH1 deficiency causing mutations.

Authors:  Justin S Poling; John A Phillips; Joy D Cogan; Rizwan Hamid
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

Review 2.  Phenotype-genotype correlations in congenital isolated growth hormone deficiency (IGHD).

Authors:  Kyriaki S Alatzoglou; Mehul T Dattani
Journal:  Indian J Pediatr       Date:  2011-12-03       Impact factor: 1.967

Review 3.  Genetic causes and treatment of isolated growth hormone deficiency-an update.

Authors:  Kyriaki S Alatzoglou; Mehul T Dattani
Journal:  Nat Rev Endocrinol       Date:  2010-10       Impact factor: 43.330

4.  A molecular basis for variation in clinical severity of isolated growth hormone deficiency type II.

Authors:  Rizwan Hamid; John A Phillips; Cindy Holladay; Joy D Cogan; Eric D Austin; Philippe F Backeljauw; Sharon H Travers; James G Patton
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

5.  Isolated growth hormone deficiency type II caused by a point mutation that alters both splice site strength and splicing enhancer function.

Authors:  N Shariat; C D Holladay; R K Cleary; J A Phillips; J G Patton
Journal:  Clin Genet       Date:  2008-06-11       Impact factor: 4.438

6.  The future of genomic endocrinology.

Authors:  Mehul T Dattani; Juan-Pedro Martinez-Barbera
Journal:  Front Endocrinol (Lausanne)       Date:  2011-05-25       Impact factor: 5.555

7.  Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension.

Authors:  Eric D Austin; John A Phillips; Joy D Cogan; Rizwan Hamid; Chang Yu; Krista C Stanton; Charles A Phillips; Lisa A Wheeler; Ivan M Robbins; John H Newman; James E Loyd
Journal:  Respir Res       Date:  2009-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.